casey analyst forecasts explosive biotech grow, page-5

"Alnylam has the most advanced technology for delivering these drugs, which every discoverer will need to get to market."

I wonder what Tekmira would have to say about this statement? Furthermore, the statement shows how little the author knows about gene therapy and fails to acknowledge that there are plenty of delivery companies out there so not "every discoverer will need" one of their own.

I think this (and other articles/reports) shows that until big $ are thrown at ddRNAi, outside of the scientific community, the alternatives will get most of the press. After all, how could an Aussie company with a market cap of $14M possibly have the IP that is the equal of American companies with MC's ~$1B?